Dr. Kenneth Rosenzweig is Professor and Chairman of the Department of Radiation Oncology at Mount Sinai School of Medicine in New York. Previously, he spent 13 years at Memorial Sloan-Kettering Cancer Center. He specializes in the treatment of thoracic malignancies, specifically lung cancer and mesothelioma, with radiation therapy.
The focus of his work has been on incorporating new technology into radiation therapy treatment for these diseases. He has specifically worked on implementing and evaluating novel techniques such as intensity modulated radiation therapy, stereotactic body radiotherapy, deep inspiration breath hold, gated radiation therapy and the incorporation of PET scans into the radiation therapy treatment planning process. He was also the principal investigator of a dose escalation study that established the maximum tolerated dose of radiation therapy that can be safely delivered with radiation therapy. He has published over 70 articles in scientific journals on his work and has authored numerous textbook chapters. He has presented his research at numerous national and international scientific meetings.
Dr. Rosenzweig has served on many committees including the Radiation Therapy Oncology Group (RTOG) Lung Committee, the RTOG Data Monitoring Committee, and the National Cancer Institute Clinical Trials Evaluation Panel. He has served as a Consultant to the International Atomic Energy Association. He attended Yale University School of Medicine and did his residency at the Joint Center for Radiation Therapy at Harvard Medical School.
MD, Yale University School of Medicine
Internship, Internal Medicine
Beth Israel Deaconess Medical Center- Harvard Medical School
Residency, Radiation Oncology
Harvard Medical School
ARRO Teacher of the Year
Basic Science Research Award
American Society for Therapeutic Radiation and Oncology
Kang H, Yorke E, Yang J, Rosenzweig K, Amols H. Evaluation of tumor motion effects on dose distribution for hypofractionated intensity-modulated radiotherapy of non-small-cell lung cancer. [abstract].
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Rosenzweig did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.